Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Orbassano (To), Italy Clinical Trials

A listing of Orbassano (To), Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (3714) clinical trials

Do you have a Lyme Rash (Bulls Eye)? If yes, then you can help! Call or visit to learn more about a diagnostic study run by Oxford Immunotex, Inc. in collaboration with Rapid Medical Research, Inc. www.rapidmedicalresearch.com Eligibility Criteria: Experiencing Lyme Rash (Bulls Eye Rash)

Phase N/A

Rivaroxaban Evaluation in Real Life Settings

To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice.

Phase N/A

LEGION Hinge Safety and Efficacy Study

The objective of this study is to demonstrate statistically significant improvements in the original Knee Society Clinical Score (KSCS) from baseline to 1 and 2 years in subjects using the LEGION™ Hinge Knee System. The focus of the 1 and 2 year analyses will be on safety and efficacy. The ...

Phase N/A

Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Improving reperfusion status is the most effective therapeutic approach for patients with acute ischemic strokes (AIS) due to large artery occlusion (LAO). Intra-Arterial Therapy (IAT) by means of mechanical thrombectomy and/or chemical fibrinolysis has been adopted worldwide to recanalize LAO strokes. IAT is now the standard of care for AIS ...

Phase N/A

Quality of Life After Stroke Using a Telemedicine-based Stroke Network

Approximately 750,000 patients suffer from ischemic stroke (AIS) annually in the United States. AIS is a a leading cause of long-term disability and the third-leading cause of mortality. Effective therapies exist to ameliorate the disability associated with AIS, but implementation of these therapies is time-sensitive. Currently, there is a shortage ...

Phase N/A

Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography

Experimental protocol 1. On the day of experiment blood samples will be collected in 3.2% citrate tubes. 2. One citrated blood tube will be centrifuged to collect plasma for biomarker measurements (C-reactive protein (CRP), fibrinogen, von Willebrand factor (vWF), interleukin (IL)-6, p-selectin, plasminogen activator inhibitor (PAI)-1, matrix metalloproteinase (MMP)-9). 3. ...

Phase N/A

Observational Study in Cystic Fibrosis Patients Using TOBI Podhaler or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

This study will include CF patients chronically colonized with P. aeruginosa enrolled in the Cystic Fibrosis Foundation (CFF) PortCF registry and using TOBI Podhaler or another FDA-approved inhaled antipseudomonal antibiotic. No therapeutic intervention will be assigned and physicians will use their discretion in choosing a treatment regimen for their patients. ...

Phase N/A

Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany

This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of of chemotherapy naïve metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality ...

Phase N/A

TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR (Endovascular Aneurysm Repair)

The primary objectives of the LIFE Study are to demonstrate the clinical cost and benefits associated with using the Ovation Prime Abdominal Stent Graft System under the least invasive conditions defined in the Fast-Track EVAR protocol. The key elements of the Fast-Track EVAR protocol include: appropriate patient selection, bilateral percutaneous ...

Phase N/A

Photodynamic Therapy for PDA in NV AMD

NV AMD remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block vascular endothelial growth factor (VEGF), a major protein mediator of angiogenesis and vascular leakage, have revolutionized treatment of NV AMD. However, less than 40% of treated patients have clinically significant improvement ...

Phase N/A